PARP1 and cancer: Therefore, PARP inhibitors are particularly effective in treating BRCA-mutated cancers due to increased cell death susceptibility from forced entry into NHEJ repair after failure to perform the HRR repair of PARP inhibitor-induced double-stranded DNA breakage [58,59,60].